TY - JOUR
T1 - The future of patient-derived xenografts in prostate cancer research
AU - Lawrence, Mitchell G.
AU - Taylor, Renea A.
AU - Cuffe, Georgia B.
AU - Ang, Lisa S.
AU - Clark, Ashlee K.
AU - Goode, David L.
AU - Porter, Laura H.
AU - Le Magnen, Clémentine
AU - Navone, Nora M.
AU - Schalken, Jack A.
AU - Wang, Yuzhuo
AU - van Weerden, Wytske M.
AU - Corey, Eva
AU - Isaacs, John T.
AU - Nelson, Peter S.
AU - Risbridger, Gail P.
N1 - Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/6
Y1 - 2023/6
N2 - Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although few prostate cancer PDXs are available in large repositories, over 330 prostate cancer PDXs have been established, spanning broad clinical stages, genotypes and phenotypes. Nevertheless, more PDXs are needed to reflect patient diversity, and to study new treatments and emerging mechanisms of resistance. We can maximize the use of PDXs by exchanging models and datasets, and by depositing PDXs into biorepositories, but we must address the impediments to accessing PDXs, such as institutional, ethical and legal agreements. Through collaboration, researchers will gain greater access to PDXs representing diverse features of prostate cancer.
AB - Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although few prostate cancer PDXs are available in large repositories, over 330 prostate cancer PDXs have been established, spanning broad clinical stages, genotypes and phenotypes. Nevertheless, more PDXs are needed to reflect patient diversity, and to study new treatments and emerging mechanisms of resistance. We can maximize the use of PDXs by exchanging models and datasets, and by depositing PDXs into biorepositories, but we must address the impediments to accessing PDXs, such as institutional, ethical and legal agreements. Through collaboration, researchers will gain greater access to PDXs representing diverse features of prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=85146616825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146616825&partnerID=8YFLogxK
U2 - 10.1038/s41585-022-00706-x
DO - 10.1038/s41585-022-00706-x
M3 - Article
C2 - 36650259
AN - SCOPUS:85146616825
SN - 1759-4812
VL - 20
SP - 371
EP - 384
JO - Nature Reviews Urology
JF - Nature Reviews Urology
IS - 6
ER -